Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (NCT07491445)
RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
Who can join: Review the eligibility criteria below.
Location: Honor Health Research Institute — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (33 Sites)
Showing the first 25 of 33 sites.
- Honor Health Research Institute — Scottsdale, Arizona
- University of California San Francisco — San Francisco, California
- H Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Comprehensive Cancer Centers of Nevada — Henderson, Nevada
- Memorial Sloan Kettering Cancer Center — New York, New York
- University of Cincinnati Cancer Center — Cincinnati, Ohio
- Taylor Cancer Research Center — Maumee, Ohio
- SCRI Oncology Partners — Nashville, Tennessee
- SCRI - Texas Oncology Dallas — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
- Huntsman Cancer Institute — Salt Lake City, Utah
- Virginia Cancer Specialists — Fairfax, Virginia
- Virginia Mason Medical Center — Seattle, Washington
- Prince of Wales Hospital — Randwick, New South Wales
- Calvary Mater Newcastle — Waratah, New South Wales
- Epworth HealthCare — East Melbourne, Victoria
- CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia — São Paulo,
- National Cancer Center - East — Kashiwa, Chiba
- Cancer Institute Hospital - Japan Foundation for Cancer Research — Koto-Ku, Tokyo
- Chiba Cancer Center — Chiba,
- NHO Kyushu Cancer Center — Fukuoka,
- Kyushu University Hospital — Fukuoka,
- Kanagawa Cancer Canter — Kanagawa,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pancreatic Cancer
- A Study of the Life Changes Experienced by Patients With Pancreatic Cancer — New York, New York
- Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer — Baltimore, Maryland
- Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma — Hartford, Connecticut
- Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer — Philadelphia, Pennsylvania
- Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer — Basking Ridge, New Jersey
- Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas — Baltimore, Maryland
Explore by condition: All Pancreatic Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.